{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:22:16Z","timestamp":1785424936640,"version":"3.56.0"},"reference-count":76,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["23-15-00188"],"award-info":[{"award-number":["23-15-00188"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"award":["23-15-00188"],"award-info":[{"award-number":["23-15-00188"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic changes in saliva are known to be closely associated with the presence of non-oral cancers, particularly breast cancer. The diagnostic and prognostic potential of salivary biomarkers in breast cancer has been demonstrated, but their applicability for assessing therapy response has not yet been established. The aim of this study was to comprehensively analyze clinical, pathological, molecular, and salivary characteristics when assessing the response to neoadjuvant chemotherapy for breast cancer. The study included 361 breast cancer patients undergoing their first course of chemotherapy and 127 healthy volunteers without breast pathologies. Saliva samples were collected from all volunteers before treatment. Saliva analysis results for amino acids, lipids, and tumor markers were compared with tumor pathomorphism assessment after breast cancer surgery. The proportion of patients with a complete response to therapy was statistically significantly lower after menopause, and in those with HER2-negative breast cancer, moderate tumor differentiation, and high estrogen and progesterone receptor expression. For the first time, a body mass index (BMI) greater than 25 and low HER2 expression (HER2-low) were shown to have an unfavorable prognosis. The criterion for selecting informative salivary metabolites was a multidirectional change in minimal and complete pathological responses to therapy compared to healthy controls. Thus, prognostically favorable signs were a decrease in the concentration of urea below 7.5 mmol\/L (OR = 1.921; 95% CI 1.061\u20134.270; p = 0.0342), a decrease in the area of the absorption band at 2957 cm\u22121 below 24 (OR = 3.875; 95% CI 1.160\u201312.70; p = 0.0003), and an increase in the concentration of cancer antigen CA27.29 above 3 U\/L (OR = 2.138; 95% CI 1.021\u20137.273; p = 0.0343) and CA-15-3 above 39 U\/L (OR = 3.896; 95% CI 1.062\u201314.07; p = 0.0072). With a simultaneous increase in both CA27.29 and CA15-3, the probability of a complete response to therapy increased (OR = 4.288; 95% CI 1.056\u201317.09; p = 0.0013). Multivariate analysis showed that an independent prognostic indicator, along with the expression status of HER2, estrogen receptors, differentiation degree, BMI, and menopause status, was the concentration of CA15-3 in saliva (AUC = 0.789, 95% CI: 0.737\u20130.842, p = 0.0001). Identifying new markers will help physicians formulate treatment plans tailored to a patient\u2019s individual risk factors, leading to increased survival and improved quality of life.<\/jats:p>","DOI":"10.3390\/ijms27104472","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:40:31Z","timestamp":1779115231000},"page":"4472","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salivary Metabolic Characteristics and Response to Neoadjuvant Systemic Therapy in Breast Cancer"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-4854","authenticated-orcid":false,"given":"Lyudmila V.","family":"Bel\u2019skaya","sequence":"first","affiliation":[{"name":"Biochemistry Research Laboratory, Omsk State Pedagogical University, 644099 Omsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.18027\/2224-5057-2021-11-4-5-13","article-title":"Characteristics of response to neoadjuvant chemotherapy in patients with aggressive biological subtypes of stage II\u2013III breast cancer. Original study","volume":"11","author":"Morozov","year":"2021","journal-title":"Malig. Tumors"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102669","DOI":"10.1016\/j.ctrv.2023.102669","article-title":"Neoadjuvant therapy in hormone Receptor-Positive\/HER2-Negative breast cancer","volume":"123","author":"Cantini","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdu118","article-title":"Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: A landmark and two-step approach analyses from the EORTC 10994\/BIG 1-00 phase III trial","volume":"25","author":"Bonnefoi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","article-title":"The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB)","volume":"268","author":"Fayanju","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","article-title":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: Recommendations from an international working group","volume":"28","author":"Provenzano","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hamy, A.S., Darrigues, L., Laas, E., De Croze, D., Topciu, L., Lam, G.T., Evrevin, C., Rozette, S., Laot, L., and Lerebours, F. (2020). Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234191"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104663","DOI":"10.1016\/j.breast.2025.104663","article-title":"Emerging technologies for monitoring breast cancer response to neoadjuvant chemotherapy: A systematic scoping review","volume":"85","author":"Wright","year":"2025","journal-title":"Breast"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e074874","DOI":"10.1136\/bmjopen-2023-074874","article-title":"Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis","volume":"13","author":"Qi","year":"2023","journal-title":"BMJ Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clbc.2022.03.003","article-title":"The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy","volume":"22","author":"Jiang","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ardakani, K.Y., Pepe, F.F., Capici, S., Clementi, T.D., and Cazzaniga, M.E. (2025). Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). Curr. Oncol., 32.","DOI":"10.3390\/curroncol32070387"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12869","DOI":"10.1038\/s41598-023-40071-2","article-title":"Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype","volume":"13","author":"Pascariello","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/2767-9764.CRC-23-0285","article-title":"Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer-Treated with Neoadjuvant Systemic Therapy","volume":"4","author":"Nguyen","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1186\/s12967-024-05790-8","article-title":"Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy","volume":"22","author":"Bertucci","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.55730\/1300-0144.5834","article-title":"Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT","volume":"54","author":"Koca","year":"2024","journal-title":"Turk. J. Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/curroncol29020055","article-title":"Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer","volume":"29","author":"Todorova","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e11857","DOI":"10.1590\/1414-431x2021e11857","article-title":"Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer","volume":"55","author":"Kneubil","year":"2022","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1186\/s12967-023-04713-3","article-title":"Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"21","author":"Omar","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104423","DOI":"10.1016\/j.breast.2025.104423","article-title":"Comprehensive genomic profiling can predict response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"80","author":"Drobniene","year":"2025","journal-title":"Breast"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10549-022-06617-0","article-title":"Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer","volume":"194","author":"Gopinath","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/1078-0432.CCR-23-1801","article-title":"RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial","volume":"29","author":"Link","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103753","DOI":"10.1016\/j.breast.2024.103753","article-title":"Prediction of response to neoadjuvant chemotherapy by MammaTyper\u00ae across breast cancer subtypes: A retrospective cross-sectional study","volume":"76","author":"Schettini","year":"2024","journal-title":"Breast"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13058-023-01607-6","article-title":"Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy","volume":"25","author":"Pavlov","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Talarico, M.C.R., Derchain, S., da Silva, L.F., Sfor\u00e7a, M.L., Rocco, S.A., Cardoso, M.R., and Sarian, L.O. (2024). Metabolomic Profiling of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy for Predicting Disease-Free and Overall Survival. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168639"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15407\/exp-oncology.2024.02.139","article-title":"Clinical significance of salivary MIR-21, -155, and -375 in patients with squamous cell carcinoma of oral cavity","volume":"46","author":"Burtyn","year":"2024","journal-title":"Exp. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"G\u00e1l, K., D\u00e1vid, P., Paholcsek, M., Barab\u00e1s, M., Szil\u00e1gyi, E., Balogh, K., Solymosi, D., Mikl\u00f3s, S., Mik\u00e1cz\u00f3, J., and Tr\u00e1si, K. (2025). Analysis of the Circulating miRNome Expression Profile in Saliva Samples After Neoadjuvant Chemoradiotherapy in a Rectal Cancer Study Population Using Next-Generation Sequencing. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110506"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1177\/00220345241262759","article-title":"Salivary Microbiome Relates to Neoadjuvant Immunotherapy Response in OSCC","volume":"103","author":"Wang","year":"2024","journal-title":"J. Dent. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"140659","DOI":"10.1016\/j.bbapap.2021.140659","article-title":"Meta-omics analysis indicates the saliva microbiome and its proteins associated with the prognosis of oral cancer patients","volume":"1869","author":"Granato","year":"2021","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1172\/JCI67228","article-title":"Oncometabolites: Linking altered metabolism with cancer","volume":"123","author":"Yang","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Perestrelo, R., and Lu\u00eds, C. (2025). Metabolomics in Breast Cancer: From Biomarker Discovery to Personalized Medicine. Metabolites, 15.","DOI":"10.3390\/metabo15070428"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kaur, R., Gupta, S., Kulshrestha, S., Khandelwal, V., Pandey, S., Kumar, A., Sharma, G., Kumar, U., Parashar, D., and Das, K. (2024). Metabolomics-Driven Biomarker Discovery for Breast Cancer Prognosis and Diagnosis. Cells, 14.","DOI":"10.3390\/cells14010005"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bel\u2019skaya, L.V. (2026). Metabolic Portrait of Breast Cancer in Mixed Saliva. Front. Biosci. (Landmark Ed.), 31.","DOI":"10.31083\/FBL47739"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1002\/cam4.4640","article-title":"Salivary biomarkers in breast cancer diagnosis: A systematic review and diagnostic meta-analysis","volume":"11","author":"Koopaie","year":"2022","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jiang, X., Jia, Y., Zhang, B., Yang, K., and Li, Y. (2025). Identification of potential biomarkers for breast cancer based on salivary metabolomics. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1655213"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bel\u2019skaya, L.V., and Dyachenko, E.I. (2024). Salivary Biomarkers in Breast Cancer: From Salivaomics to Salivaoncoomics. Front. Biosci. (Landmark Ed.), 29.","DOI":"10.31083\/j.fbl2907253"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"119836","DOI":"10.1016\/j.cca.2024.119836","article-title":"A critical appraisal of the role of metabolomics in breast cancer research and diagnostics","volume":"561","author":"Gadwal","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Li, J., Eu, J.Q., Kong, L.R., Wang, L., Lim, Y.C., Goh, B.C., and Wong, A.L.A. (2020). Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. Molecules, 25.","DOI":"10.3390\/molecules25204831"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e26001","DOI":"10.62063\/rev-22","article-title":"The predictive value of metabolomic-related biomarkers in breast cancers: Current approaches in biotechnology","volume":"2","author":"Nishanthan","year":"2026","journal-title":"EUCHEMBIOJ Rev."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Qian, B., Yang, J., Zhou, J., Hu, L., Zhang, S., Ren, M., and Qu, X. (2022). Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.955250"},{"key":"ref_39","first-page":"e25229","article-title":"Molecular Subtypes As Emerging Predictors of Clinicopathological Response to Neoadjuvant Chemotherapy (NACT) in Locally Advanced Breast Cancer (LABC): A Single-Centre Experience in Western India","volume":"14","author":"Sharma","year":"2022","journal-title":"Cureus"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1007\/s12094-025-03856-7","article-title":"Predictive score for response to neoadjuvant chemotherapy in early-stage HR\u2009+\u2009\/HER2- breast cancer","volume":"27","author":"Coelho","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jjco\/hyz012","article-title":"Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"49","author":"Jain","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bel\u2019skaya, L.V. (2025). HER2-low Breast Cancer: Salivary Metabolic Features and Therapeutic Perspectives. Front. Biosci. (Sch. Ed.), 17.","DOI":"10.31083\/FBS36652"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12282-022-01431-4","article-title":"HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC","volume":"30","author":"Li","year":"2023","journal-title":"Breast Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s12094-022-03062-9","article-title":"The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer","volume":"25","author":"Wang","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clbc.2024.05.001","article-title":"Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis","volume":"24","author":"Liu","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Solomatin, D.V., Sarf, E.A., and Bel\u2019skaya, L.V. (2025). Metabolic Features of Saliva Before and After Breast Cancer Surgery. Metabolites, 15.","DOI":"10.3390\/metabo15110693"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cheung, S.M., Chan, K.S., Senn, N., Husain, E., Sharma, R., McGoldrick, T., Gagliardi, T., Masannat, Y., and He, J. (2024). Peri-Tumoural Lipid Composition and Hypoxia for Early Immune Response to Neoadjuvant Chemotherapy in Breast Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179303"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1878-0261.13216","article-title":"Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: A novel metabolomics approach","volume":"16","author":"Camacho","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8976","DOI":"10.1038\/s41598-021-88258-9","article-title":"SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer","volume":"11","author":"Zhao","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13058-024-01956-w","article-title":"Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: A retrospective longitudinal study","volume":"27","author":"Fang","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Silva, A.A.R., Cardoso, M.R., Oliveira, D.C., Godoy, P., Talarico, M.C.R., Guti\u00e9rrez, J.M., Rodrigues Peres, R.M., de Carvalho, L.M., Miyaguti, N.A.D.S., and Sarian, L.O. (2024). Plasma Metabolome Signatures to Predict Responsiveness to Neoadjuvant Chemotherapy in Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16132473"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Jingjing, Z., Kun, W., Yanyu, Q., Mengjie, Z., Yunqing, C., Yulong, T., Xuelong, J., Xiaojie, T., Haitao, J., and Feng, H. (2025). Radiation therapy induced intestinal barrier damage and repair process\u2014Differences in salivary metabolites and monitoring of intestinal barrier function. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1590219"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41586-024-07179-5","article-title":"Dopamine receptor D2 confers colonization resistance via microbial metabolites","volume":"628","author":"Scott","year":"2024","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Fu, Y., Lyu, J., and Wang, S. (2023). The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1277102"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1968257","DOI":"10.1080\/19490976.2021.1968257","article-title":"Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease","volume":"13","author":"Li","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Parada Venegas, D., De la Fuente, M.K., Landskron, G., Gonz\u00e1lez, M.J., Quera, R., Dijkstra, G., Harmsen, H.J.M., Faber, K.N., and Hermoso, M.A. (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01486"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.radonc.2018.06.022","article-title":"Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer","volume":"128","author":"Jia","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1080\/19490976.2020.1737487","article-title":"Specific gut microbiome signature predicts the early-stage lung cancer","volume":"11","author":"Zheng","year":"2020","journal-title":"Gut Microbes"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"109886","DOI":"10.1016\/j.celrep.2021.109886","article-title":"Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models","volume":"37","author":"Dong","year":"2021","journal-title":"Cell Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12943-024-02108-6","article-title":"Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer","volume":"23","author":"Chen","year":"2024","journal-title":"Mol. Cancer."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Wang, K., Zhang, J., Zhang, Y., Xue, J., Wang, H., Tan, X., Jiao, X., and Jiang, H. (2024). The recovery of intestinal barrier function and changes in oral microbiota after radiation therapy injury. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1288666"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Claiborne, M.D., and Leone, R. (2022). Differential glutamine metabolism in the tumor microenvironment\u2014Studies in diversity and heterogeneity: A mini-review. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1011191"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Xu, E., Ji, B., Jin, K., and Chen, Y. (2023). Branched-chain amino acids catabolism and cancer progression: Focus on therapeutic interventions. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1220638"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yang, L., Zhu, J., Wang, L., He, L., Gong, Y., and Luo, Q. (2023). A novel risk score model based on gamma-aminobutyric acid signature predicts the survival prognosis of patients with breast cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1108823"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rushing, B.R., Molina, S., and Sumner, S. (2023). Metabolomics Analysis Reveals Altered Metabolic Pathways and Response to Doxorubicin in Drug-Resistant Triple-Negative Breast Cancer Cells. Metabolites, 13.","DOI":"10.3390\/metabo13070865"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.1245\/s10434-025-17397-4","article-title":"Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer","volume":"32","author":"Zhu","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.2147\/CMAR.S246349","article-title":"HIF-1\u03b1, TWIST-1 and ITGB-1, associated with Tumor Stiffness, as Novel Predictive Markers for the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.clbc.2022.05.007","article-title":"Plasma Profile of Immune Determinants Predicts Pathological Complete Response in Locally Advanced Breast Cancer Patients: A Pilot Study","volume":"22","author":"Miceli","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/sj.bjc.6605565","article-title":"8-Hydroxydeoxyguanosine: A new potential independent prognostic factor in breast cancer","volume":"102","author":"Sova","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"639","DOI":"10.31557\/APJCP.2025.26.2.639","article-title":"Expression Analysis of Oxidative Stress Markers 8-hydroxydeoxyguanosine and Protein Carbonyl in Breast Cancer and Their associations with Certain Immunological and Tumor Markers","volume":"26","author":"Yahia","year":"2025","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Dyachenko, E.I., and Bel\u2019skaya, L.V. (2025). How does breast cancer heterogeneity determine changes in tumor marker levels in saliva?. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47040216"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5937\/jomb0-43900","article-title":"Can pretreatment lactate dehydrogenase to albumin ratio predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients?","volume":"44","year":"2025","journal-title":"J. Med. Biochem."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Pelizzari, G., Basile, D., Zago, S., Lisanti, C., Bartoletti, M., Bortot, L., Vitale, M.G., Fanotto, V., Barban, S., and Cinausero, M. (2019). Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. Cancers, 11.","DOI":"10.3390\/cancers11091243"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.bcp.2011.06.007","article-title":"Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy","volume":"82","author":"Glorieux","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102944","DOI":"10.1016\/j.vibspec.2019.102944","article-title":"Analysis of the lipid profile of saliva in ovarian and endometrial cancer by IR Fourier spectroscopy","volume":"104","author":"Sarf","year":"2019","journal-title":"Vib. Spectrosc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1039\/B518076G","article-title":"Analytical performances of FT-IR spectrometry and imaging for concentration measurements within biological fluids, cells, and tissues","volume":"131","author":"Petibois","year":"2006","journal-title":"Analyst"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4472\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:13:07Z","timestamp":1779423187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":76,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27104472"],"URL":"https:\/\/doi.org\/10.3390\/ijms27104472","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]}}}